How many investments has JDRF T1D Fund made?

JDRF T1D Fund has 37 tracked investments, 5 of which have exited.

What stage does JDRF T1D Fund invest at?

JDRF T1D Fund invests at the Seed, Series A, Series B, Late Stage stages.

Where is JDRF T1D Fund located?

JDRF T1D Fund is headquartered in Boston, US.

Who does JDRF T1D Fund co-invest with?

JDRF T1D Fund most often shares deals with ARCH Venture Partners, Alpha Wave Global, F-Prime Capital, among 58 tracked co-investors.

JDRF T1D Fund

Impact investor

Boston · Seed–Late Stage · 30 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into JDRF T1D Fund

2,975 people in our graph share verified history with the JDRF T1D Fund team — schools, employers, funds. One of them is your warm intro.

René Kuijtenunlockedknows Katie Ellias · together at McKinsey & Company (overlapped)

×4knows the team · via Harvard University

×2knows the team · via Yale University

×2knows the team · via University of California, Berkeley

knows the team · via Imperial College London

knows the team · via 2hearts

✨ Fox Verdict

Investment thesis

The T1D Fund deploys catalytic capital and scientific expertise to accelerate treatments and cures for type 1 diabetes. It positions itself as a collaboration platform that de-risks investments to draw additional investors into the T1D space, creating a flywheel effect. The fund partners with innovators advancing disease-modifying therapies and reinvests all returns to sustain a continuous cycle that funds foundational research and program development. Its team combines venture, investment banking, pharmaceutical, company-building, and business development experience, and it manages an active portfolio of more than 25 companies focused on curing and treating T1D.

Invests inBiotech Digital Health Healthtech Impact & Social Good Medical Devices Boston Global United States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Late Stage

Boston, Massachusetts, US

Instruments

Equity

Founded

2016

AUM

$250M

Tracked investments

IPOs

Acquisitions

Team · 30 people

from the firm's website & curated & public directories

Lucio Iannone· Managing Director· Boston, Massachusetts, United Statesin

Lucio Iannone is a Senior Managing Director at T1D Fund, where he focuses on early-stage biotech investments. He works with scientists and entrepreneurs developing medical technologies and therapeutic applications.

Elizabeth Mily· CEO

CEO of the T1D Fund, leading the Fund's mission to accelerate therapeutic innovation in the T1D space through relationships with investors, pharma, and biotech companies.

e•••@t1dfund.orgreveal

Sylvia Tobé· Managing Director· Cambridge, Massachusetts, United Statesin

A biotech professional with over a decade of experience across venture investing, company creation, and translational science. Before the T1D Fund she was a Principal at Omega Funds focused on early-stage investing, and previously spent nearly seven years at Ra Pharmaceuticals; she holds a Ph.D. in Biochemistry from Pierre and Marie Curie University.

s•••@t1dfund.orgreveal

Adam King· Managing Director· San Francisco, California, United States

a•••@groundforcecapital.comreveal

Katie Ellias· Managing Partner· Boston, Massachusettsin 𝕏

Katie Ellias is a Venture Partner at Zubi Capital with over a decade of venture capital experience in life sciences, including biotech, medical devices, and digital health. She previously served as Managing Director of a single disease impact fund focused on venture philanthropy from 2018 to 2024, and has held board director and observer positions at 12+ early and later-stage companies across the US, Canada, and Europe. Her background includes product launches in interventional cardiology and expertise in cardiac surgery, structural heart, diabetes, and global M&A transactions.

Steven St. Peter· Managing Director· Boston, Massachusetts𝕏

Daniel Flicker· Principal· Boston, Massachusetts, United Statesin

Daniel Flicker joined the T1D Fund in January 2025. He previously was a Senior Associate at Novo Holdings investing in biotech and medtech, and earlier worked in healthcare investment banking and equity research at Chardan and in life sciences consulting at L.E.K. He holds a Ph.D. in Systems Biology from Harvard and a B.A. in Biochemistry from Columbia.

d•••@t1dfund.orgreveal

Karim El-Ghawi· Director of Operations· Germanyin

Aaron J. Kowalski· Board of Directors· New York, New York, United Statesin

Aaron J. Kowalski is Chief Executive Officer of Breakthrough T1D, a global type 1 diabetes research and advocacy organization formerly known as JDRF, which he joined in 2004 and where he previously served as Chief Mission Officer. He has authored articles on T1D research, including an artificial pancreas roadmap adopted by the diabetes industry and a New England Journal of Medicine study on continuous glucose monitors, and has advised Congress, the U.S. Department of Health and Human Services, and the U.S. Food and Drug Administration on T1D therapy access and regulation. Diagnosed with T1D at age 13, he holds a doctorate in microbiology and molecular genetics from Rutgers University and has completed 20 marathons.

Brady Bohrmann· Investment Committee

Dan McNamara· Head of Strategy and Industry Engagement· New York, New York, United Statesin

Newly appointed Head of Strategy & Industry Engagement, tasked with growing the Fund's brand and driving greater interest in T1D investments. He brings over 15 years of corporate strategy, operations, and business development experience, most recently as VP of Enterprise Governance and Strategy & Business Development Operations at Bristol Myers Squibb, where he helped lead over $100B in M&A and business development activity.

Eric Shen· Chief of Staff· Boston, Massachusetts, United Statesin

Eric Shen is Chief of Staff at the T1D Fund. He has more than eight years of experience in corporate development and operations at venture-backed biotech and medtech companies, along with experience working within venture capital environments. His work has spanned financing, partnerships, investor relations, and strategic execution at early- and growth-stage life sciences companies.

Frank Martin· Investment Committee

Biotechnology venture advisor.

Grant Beard· Board of Directors

Jason Snipe· Investment Committee

Founder and Chief Investment Officer of Odyssey Capital Advisors.

Joe Lacher· Chair, Board of Directors

John Cammett· Board of Directors / Investment Committee

Karen Jordan· Board of Directors

Matt Williams· Director of Operations· New York City Metropolitan Areain

Matt Williams serves as Director of Operations at T1D Fund. He earned a B.S. in Sociology of Business, Organization, and Non-Profits with a leadership minor from the University of Minnesota Twin Cities in 2021, and holds NREMT and EMSRB certifications, OSHA-30 certification, and a ServSafe Food Manager certification. He relocated to Boston, MA in August 2022.

Mike Boyle· Board of Directors

Peter Gottlieb· Investment Committee

Professor of Pediatrics and Medicine at the Barbara Davis Center, University of Colorado School of Medicine.

Peyman Hosseinchi· Senior Associate· Boston, Massachusetts, United Statesin

Teresa Foy· Investment Committee· Hong Kong SAR

Immunologist and biopharmaceutical R&D leader.

Morgan Janes· Associate· Israelin

Morgan Janes joined the T1D Fund as an Associate in October 2024. She earned her Ph.D. at MIT as an NSF Fellow researching bioinspired materials for vaccine delivery, previously held fellowships at MPM Capital and Artis Ventures, and holds a B.S. in Bioengineering from the University of Maryland.

m•••@t1dfund.orgreveal

Valerie Su· Associate· Cambridge, Massachusetts, United Statesin

Valerie Su joined the T1D Fund in August 2024. She previously worked as a Scientist at Sanofi advancing early drug discovery programs in autoimmune disease and completed an internship in External Innovation. She holds a Ph.D. in Pharmacology from Yale University and a B.A. in Molecular and Cell Biology from UC Berkeley.

v•••@t1dfund.orgreveal

Yash Malliwal· Senior Analyst

Yash Malliwal joined the T1D Fund in January 2024. He previously worked as an Associate Consultant at Clarion Healthcare (now Lumanity Strategy Consulting), advising biopharmaceutical clients on commercial due diligence, business development, product planning, and operations strategy. He holds a B.A. in Biology from Colby College.

y•••@t1dfund.orgreveal

Ethan Sohn· Associate· New York, New York, United Statesin

e•••@toyota.venturesreveal

Heather McManus· Strategic Advisor· Los Angeles Metropolitan Areain

Heather McManus is Chief Learning Officer at NewSchools Venture Fund. She has more than 21 years of experience in education management and organizational leadership, with a background that includes school management, instructional design, whole-system improvement, human resources, and hiring.

Jay Shepard· Head of Strategy & Industry Engagement· Englewood, Colorado, United Statesin

Jay P. Shepard is a Venture Partner at Catalys Pacific, a venture group focused on licensing drug programs and creating companies in the US and Japan, and serves on the boards of two of its portfolio companies, Aculys and Pathalys. He previously held chief executive roles at Versartis (later merged with Aravive), NextWave Pharmaceuticals, Ilypsa, and Relypsa, and was an Executive Partner at Sofinnova Ventures from 2008 to 2015. He serves as Chairman of the Board of the Christopher & Dana Reeve Foundation and as a board member of Inovio Pharmaceuticals, Ironwood Pharmaceuticals, and Esperion, and holds a B.S. in business administration from the University of Arizona.

Valentin Wierse· Senior Associate· Greater Munich Metropolitan Areain

v•••@b2venture.vcreveal

What they invest in

from 34 of 37 portfolio companies

Biotech ×31Healthtech ×20Medical Devices ×15Digital Health ×7Deep Tech ×5AI & Machine Learning ×4Advanced Manufacturing ×1Fintech ×1

HQs:United States×15Canada×2France×2United Kingdom×1Italy×1Japan×1

Who they back

founder profiles across 13 portfolio companies

38%

solo founders

5 of 13 mapped founding teams

38%

repeat founders

of 13 founders with career history

Founding team size:solo founder×52 founders×33 founders×34+ founders×2

Where their founders studiedfrom 11 founders with education data

University of British Columbia ×2

What their founders studiedfrom 12 founders with field-of-study data

Engineering ×4Medicine ×4Life Sciences ×3Business & Management ×2Chemistry ×2

Investments · 37 tracked

founders shown can be your intro path

By year:2023 · 1 2022 · 3 2021 · 2 2020 · 4 2019 · 111 dated

Immunocoreimmunocore.com inNASDAQ: IMCRJul 2022

Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.

BiotechHealthtechAbingdon, Oxfordshire

Brian Di Donato(Chief Financial Officer)David Berman(Head of Research and Development)in Tina St. Leger(Chief Human Resources Officer)in Bahija Jallal(Chief Executive Officer)inRobert Perez(Director)Peter Ratcliffe(Director)

Co-investorsAvego BioScience Capital

Vtvtherapeuticsvtvtherapeutics.com in 𝕏NASDAQ: VTVT

vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.

BiotechDigital HealthMedical DevicesHigh Point, US

Rudy Howard(Executive Officer)in Stephen Holcombe(Executive Officer)inLarry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)Paul Sekhri(Chairman, President, and Chief Executive Officer)in Michael Tung(Executive Vice President and Chief Financial Officer)in

Co-investorsSamsara BioCapital

Adaxion Therapeuticsadaxiontx.com in

ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses.

BiotechDeep Tech

Co-investorsVivo Capital

Aera Therapeuticsaeratx.com in 𝕏

Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US

Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)

Co-investorsARCH Venture Partners Lux Capital F-Prime Capital GV (Google Ventures)Newpath Partners

Aspect Biosystemsaspectbiosystems.com in

Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues.

AI & Machine LearningBiotechLongevity

Tamer Mohamed(Founder & CEO)in Sam Wadsworth(Co-founder & Chief Scientific Officer)inSimon Beyer(Co-founder & Chief Technology Officer)inLeela Paris(Chief Technical Operations Officer)in Mike Scott(Chief Development Officer)inRay Smith(Chief Financial Officer)in

Co-investorsAngel Forum Civilization Ventures Management, Llc InBC Investment Corp.Page One Ventures Pallasite Ventures Pangaea Ventures Us Inc.+5 more

Bigfoot Biomedicalbigfootbiomedical.com in

Bigfoot Biomedical develops a diabetes management system that combines continuous glucose monitor data with a doctor's instructions to give insulin dose recommendations.

Digital HealthHealthtechMedical DevicesNew York, US

Jeffrey Brewer(Executive Officer, Director)inBryan Mazlish(Executive Officer, Director)inJon Brilliant(Executive Officer)

Co-investorsWinklevoss Capital Xplorer Capital Janus Henderson Investors Smile Group Visionnaire Ventures, Llc

Biolinqbiolinq.me in

Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.

BiotechDigital HealthHealthtechMedical DevicesSan Diego, US

Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)

Board Daniel Bradbury(Director)in Lana Ghanem(Director)

Co-investorsAlpha Wave Global Beyond Capital BioBrit Aphelion Capital Hikma Ventures LifeSci Venture Partners +1 more

Code Biotherapeuticscodebiotx.com in 𝕏Jun 2022

Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.

BiotechDeep TechHealthtechHatfield, US

Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in

BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)

Co-investorsNew Enterprise Associates (NEA)4BIO Capital Amgen Ventures Hatteras Venture Partners Northpond Ventures Takeda Ventures +1 more

Cour Pharmacourpharma.com in 𝕏

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.

BiotechHealthtech

Co-investorsAlpha Wave Global Lumira Ventures Roche Venture Fund Angelini Ventures

Diasomediasome.com in

Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases.

BiotechHealthtechMedical Devices

Robert Geho(Co-Founder, Chief Executive Officer)inW. Blair Geho(Co-Founder, Chief Scientific Officer)in

Co-investorsMedicxi

DiogenX’s websitediogenx.com in

DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.

BiotechDeep TechDigital HealthHealthtechMarseille, FR

Benjamin Charles(Co-Founder & CEO)inPatrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in

Co-investorsAdBio partners Roche Venture Fund Boehringer Ingelheim Venture Fund Sunstone Capital

Egle Txegle-tx.com in

Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.

Biotech

Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in

Board Michel Detheux(Chairman)in

Co-investorsEQT Life Sciences Fund+

Eledoneledon.com in 𝕏

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.

AI & Machine LearningBiotechMedical Devices

Steven Perrin(President and Chief Scientific Officer)

Co-investorsBiotechnology Value Fund Newpath Partners

Entheraentherapharmaceuticals.com in

Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.

BiotechHealthtechMilan, IT

Co-investorsSofinnova Partners Indaco Venture Partners Roche Venture Fund AbbVie

GentiBiogentibio.com in 𝕏

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)inDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)inTom Wickham(Chief Scientific Officer)

Co-investorsNovartis Venture Fund OrbiMed RA Capital

i2O Therapeutics inDec 2020 · $4M

Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology

BiotechSaratoga, US

Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in

Co-investors7G BioVentures Sanofi Ventures

Imtherapeuticsimtherapeutics.com in

Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers.

Biotech

Inversagoinversago.comSep 2020 · $35Macquired by Novo Nordisk

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsAmorChem Genesys Capital New Enterprise Associates (NEA)Tarnagulla Ventures adMare BioInnovations Amgen Ventures +2 more

Jaguar Gene Therapyjaguargenetherapy.com in

Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.

BiotechHealthtechMedical Devices

Joseph Nolan in

Co-investorsAIF ARCH Venture Partners Deerfield Management Company Goldman Sachs Samsung Ventures

Kriyakriya.co inMay 2022 · $270M

Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.

FintechSaaS

Anil Stocker(Founder)in

Co-investorsMouro Capital Northzone Bluebird Ventures Foresite Capital Narya Capital Patient Square Capital +2 more

Kriya Therapeuticskriyatherapeutics.com in 𝕏Jun 2021

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.

BiotechHealthtechMorrisville, US

Shankar Ramaswamy(Co-Founder, Chairman & CEO)in Roger Jeffs(Co-Founder & Vice Chairman)inFraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)in Shankar Ramaswamy, M.D.(Founder)in Michele Stone(Chief Scientific Officer)inKatherine Eade(Chief Legal Officer)

Co-investorsPatient Square Capital Premji Invest Amplo Ventures Bluebird Ventures Foresite Capital Narya Capital +2 more

Mozart Therapeuticsmozart-tx.com

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in

Co-investorsARCH Venture Partners MRL Ventures Fund Ono Venture Investment, Inc.Pfizer Venture Investments Sofinnova Partners Alexandria +4 more

Protomerprotomer.com inNov 2020

Protomer develops dynamic medicines that modify their activity in the body to increase potency where and when needed.

BiotechMedical DevicesPasadena, US

Alborz Mahdavi(CEO)in

Proventionbioproventionbio.com in 𝕏acquired by Sanofi

Sanofi is a pharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients globally.

BiotechHealthtechMedical Devices

Repertoire Immune Medicinesrepertoire.com in 𝕏Mar 2020

Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtech

Torben Straight Nissen(Chief Executive Officer)in Anthony Coyle(President, Research and Development)inRobert Andtbacka(Chief Medical Officer)in John Delyani(Chief Business Officer)inJan Kisielow(Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.)in

Co-investorsFlagship Pioneering SoftBank Vision Fund

Sabsab.bio in 𝕏

SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates.

BiotechDigital HealthHealthtechMedical Devices

Eddie J Sullivan(Founder)in

Sana Biotechnologysana.com in

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

BiotechHealthtechMedical DevicesSeattle, US

Richard Mulligan(Director)inHans Bishop(Director)Steve Harr(President and Chief Executive Officer)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)

Board Geoffrey von Maltzahn(Director)in

Co-investorsAmerican Family Ventures ARCH Venture Partners F-Prime Capital Flagship Pioneering Innovating Capital Manta Ray Ventures +1 more

Semma Therapeuticssemma-tx.comacquired by Vertex Pharmaceuticals · Sep 2019 · $950M

Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.

BiotechCambridge, US

Robert Millman(Executive Officer, Director)

Board Todd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)

Co-investorsARCH Venture Partners F-Prime Capital ORI Capital Slater Technology Fund Eight Roads Ventures MPM BioImpact

Seraxisseraxis.com in 𝕏Sep 2023

Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.

BiotechHealthtechGermantown, US

William L. Rust(Executive Officer, Director, Promoter)in Carole Welsch(Executive Officer)inGi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)

Board James N. Topper(Director)

Co-investorsMaryland TEDCO TEDCO Frazier Life Sciences

Sonoma Biotherapeuticssonomabio.com in 𝕏Jul 2021

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Jeffrey Bluestone(Executive Officer, Director, Promoter)in

BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)

Co-investors8VC ARCH Venture Partners Frazier Life Sciences LAV Lifeforce Capital Lilly Asia Ventures +1 more

Zucarazucara.ca

Zucara Therapeutics is a biotech company developing a once-daily therapeutic intended to prevent hypoglycemia (low blood sugar) in people with diabetes.

BiotechDigital HealthHealthtech

Co-investorsToronto Innovation Acceleration Partners

オリヅルセラピューティクス株式会社orizuru-therapeutics.com

Orizuru Therapeutics develops cellular therapy products and regenerative medicine treatments utilizing iPS cell-related technology.

BiotechHealthtechMedical DevicesFujisawa, JP

Kenji Nonaka(代表取締役 (CEO))

Co-investorsKyoto University Innovation Capital SMBC Venture Capital Sumitomo Mitsui Trust Bank

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Capillary BioCapillary Biomedical Diasome Pharmaceuticals ImmunoMolecular TherapeuticsPandiontx

Exits · 5

2 IPOs · 3 acquisitions

ImmunocoreNASDAQ: IMCRVtvtherapeuticsNASDAQ: VTVTInversagoacq. by Novo NordiskProventionbioacq. by SanofiSemma Therapeuticsacq. by Vertex Pharmaceuticals

Portfolio news

latest coverage across their companies

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 | Eledon Pharmaceuticals, Inc.

Eledon · ir.eledon.com · Sep 3, 2026

How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback - Simply Wall St News

Immunocore · simplywall.st · Aug 14, 2026

Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value Indexes - What's Changed - Simply Wall St News

Sana Biotechnology · simplywall.st · Jul 8, 2026

Sell or Invest in Kriya Therapeutics Stock Pre-IPO

Kriya Therapeutics · nasdaqprivatemarket.com · Apr 3, 2026

Aera Therapeutics: A High-Stakes Platform Bet Hinging on 2026 Clinical Catalyst for AERA-109

Aera Therapeutics · ainvest.com · Mar 22, 2026

Jaguar Gene Therapy completes Cohort I patient dosing in JAG201 clinical trial

Jaguar Gene Therapy · clinicaltrialsarena.com · Feb 25, 2026

Kriya Therapeutics raises $313.3 funding | Ophthalmology Times - Clinical Insights for Eye Specialists

Kriya · ophthalmologytimes.com · Dec 12, 2025

FDA clears Biolinq's color-coded sensor patch for glucose ranges

Biolinq · fiercebiotech.com · Sep 29, 2025

Frequently asked questions

How many investments has JDRF T1D Fund made?: JDRF T1D Fund has 37 tracked investments, 5 of which have exited.
What stage does JDRF T1D Fund invest at?: JDRF T1D Fund invests at the Seed, Series A, Series B, Late Stage stages.
What sectors does JDRF T1D Fund focus on?: JDRF T1D Fund focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
Where is JDRF T1D Fund located?: JDRF T1D Fund is headquartered in Boston, US.
Who does JDRF T1D Fund co-invest with?: JDRF T1D Fund most often shares deals with ARCH Venture Partners, Alpha Wave Global, F-Prime Capital, among 58 tracked co-investors.

Images

Co-investors · 7

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 2

Code Biotherapeutics Inversago

$200K – $40M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 1

i2O Therapeutics

$5M

Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.

Both backed · 1

Code Biotherapeutics

$500K – $4M

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund, established in 2010, invests in biotechnology companies developing therapeutics in immuno-oncology, regenerative medicine, and gene therapy, including platform technologies and novel vaccines. The fund targets early-stage companies addressing unmet medical needs through translational research and scientific innovation.

Both backed · 1

$16.2M

Both backed · 1

Domain Associates is a venture capital firm founded in 1985 that invests in life sciences companies. The firm operates as a limited liability company.

$200K – $15M

Cultivian Sandbox Ventures

Cultivian Sandbox Ventures is a venture capital firm investing in innovative food and agriculture companies that commercialize solutions across the food and agriculture value chain.

$5M – $15M

Firms observed investing alongside JDRF T1D Fund, from public investor directories. Shared companies are the overlap with JDRF T1D Fund's recorded portfolio.

Similar investors

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Syridex Bio identifies emerging areas of science and medicine to invest in innovations addressing unmet medical needs, applying a health-equity lens to opportunities that can improve outcomes across diverse patient populations.

iNetworks

iNetworks is a Pittsburgh-based private equity investment fund and advisory practice, founded in 1999, focused on healthcare, life science, and technology companies. It provides capital, management, and operational expertise across funding stages from early-stage to IPOs and LBOs.